{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T06:00:01Z","timestamp":1790316001954,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004794","name":"CNRS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007486","name":"Universit\u00e9 Paris-Sud","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007486","id-type":"DOI","asserted-by":"publisher"}]},{"name":"la Ligue contre le Cancer Comit\u00e9 des Hauts de Seine","award":["4FI10626MIUR"],"award-info":[{"award-number":["4FI10626MIUR"]}]},{"DOI":"10.13039\/501100004097","name":"Fondation ARC","doi-asserted-by":"publisher","award":["SFI20111203965"],"award-info":[{"award-number":["SFI20111203965"]}],"id":[{"id":"10.13039\/501100004097","id-type":"DOI","asserted-by":"publisher"}]},{"name":"French MENSR"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.canlet.2018.06.001","type":"journal-article","created":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T17:57:50Z","timestamp":1528221470000},"page":"103-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Antitumor activity of nanoliposomes encapsulating the novobiocin analog 6BrCaQ in a triple-negative breast cancer model in mice"],"prefix":"10.1016","volume":"432","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8065-4439","authenticated-orcid":false,"given":"F\u00e9lix","family":"Sauvage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3194-961X","authenticated-orcid":false,"given":"Elias","family":"Fattal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walhan","family":"Al-Shaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Denis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Brotin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Denoyelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Blanc-Fournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balthazar","family":"Toussaint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Messaoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouad","family":"Alami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Barratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Vergnaud-Gauduchon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1\u20133","key":"10.1016\/j.canlet.2018.06.001_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0014-5793(04)00229-7","article-title":"Hsp90 isoforms: functions, expression and clinical importance","volume":"562","author":"Sreedhar","year":"2004","journal-title":"FEBS Lett."},{"issue":"8","key":"10.1016\/j.canlet.2018.06.001_bib2","first-page":"488","article-title":"Targeting multiple signal transduction pathways through inhibition of Hsp90","volume":"82","author":"Zhang","year":"2004","journal-title":"J. Mol. Med. Berl. Ger."},{"issue":"3","key":"10.1016\/j.canlet.2018.06.001_bib3","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2174\/138161213804143725","article-title":"The therapeutic target Hsp90 and cancer hallmarks","volume":"19","author":"Miyata","year":"2013","journal-title":"Curr. Pharmaceut. Des."},{"issue":"5","key":"10.1016\/j.canlet.2018.06.001_bib4","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.canlet.2018.06.001_bib5","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.bbamcr.2011.08.006","article-title":"Quality control and fate determination of Hsp90 client proteins","volume":"1823","author":"Theodoraki","year":"2012","journal-title":"Biochim. Biophys. Acta BBA - Mol. Cell Res."},{"issue":"2","key":"10.1016\/j.canlet.2018.06.001_bib6","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1379\/1466-1268(2003)008<0105:WIAC>2.0.CO;2","article-title":"What is a Co-Chaperone?","volume":"8","author":"Caplan","year":"2003","journal-title":"Cell Stress Chaperones"},{"issue":"1","key":"10.1016\/j.canlet.2018.06.001_bib7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0959-440X(99)00047-0","article-title":"Structure and in vivo function of Hsp90","volume":"10","author":"Pearl","year":"2000","journal-title":"Curr. Opin. Struct. Biol."},{"issue":"9","key":"10.1016\/j.canlet.2018.06.001_bib8","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1074\/jbc.M105568200","article-title":"A nucleotide-dependent molecular switch controls ATP binding at the C-Terminal domain of Hsp90 N-terminal nucleotide binding unmasks a C-Terminal binding pocket","volume":"277","author":"S\u00f6ti","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.canlet.2018.06.001_bib9","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1039\/C4CC07284G","article-title":"N-terminal and C-Terminal modulation of Hsp90 produce dissimilar phenotypes","volume":"58","author":"Wang","year":"2015","journal-title":"Chem. Commun. Camb. Engl."},{"issue":"6","key":"10.1016\/j.canlet.2018.06.001_bib10","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00018-008-7458-y","article-title":"New insights into the mechanism of heat shock response activation","volume":"65","author":"Shamovsky","year":"2008","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.canlet.2018.06.001_bib11","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1146\/annurev-biochem-060809-095203","article-title":"Regulation of HSF1 function in the heat stress response: implications in aging and disease","volume":"80","author":"Anckar","year":"2011","journal-title":"Annu. Rev. Biochem."},{"issue":"26","key":"10.1016\/j.canlet.2018.06.001_bib12","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.2174\/092986708786242895","article-title":"Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket","volume":"15","author":"Donnelly","year":"2008","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.canlet.2018.06.001_bib13","series-title":"Heat Shock Protein Inhibitors","first-page":"1","article-title":"Targeting the C-Terminus of Hsp90 as a cancer therapy","author":"McConnell","year":"2015"},{"key":"10.1016\/j.canlet.2018.06.001_bib14","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ejmech.2014.06.067","article-title":"Synthesis and antiproliferative activity of novobiocin analogues as potential Hsp90 inhibitors","volume":"83","author":"Audisio","year":"2014","journal-title":"Eur. J. Med. Chem."},{"issue":"5","key":"10.1016\/j.canlet.2018.06.001_bib15","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/cmdc.201000489","article-title":"Discovery and biological activity of 6BrCaQ as an inhibitor of the Hsp90 protein folding machinery","volume":"6","author":"Audisio","year":"2011","journal-title":"ChemMedChem"},{"issue":"12","key":"10.1016\/j.canlet.2018.06.001_bib16","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nnano.2007.387","article-title":"Nanocarriers as an emerging platform for cancer therapy","volume":"2","author":"Peer","year":"2007","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.canlet.2018.06.001_bib17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jconrel.2017.01.013","article-title":"Heat shock proteins and cancer: how can nanomedicine Be harnessed?","volume":"248","author":"Sauvage","year":"2017","journal-title":"J. Contr. Release"},{"issue":"1\u20132","key":"10.1016\/j.canlet.2018.06.001_bib18","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijpharm.2015.12.053","article-title":"Formulation and in vitro efficacy of liposomes containing the Hsp90 inhibitor 6BrCaQ in prostate cancer cells","volume":"499","author":"Sauvage","year":"2016","journal-title":"Int. J. Pharm. (Amst.)"},{"key":"10.1016\/j.canlet.2018.06.001_bib19","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2147\/IJN.S68861","article-title":"Liposomes as nanomedical devices","volume":"10","author":"Bozzuto","year":"2015","journal-title":"Int. J. Nanomed."},{"issue":"1\u20132","key":"10.1016\/j.canlet.2018.06.001_bib20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0168-3659(99)00248-5","article-title":"Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review","volume":"65","author":"Maeda","year":"2000","journal-title":"J. Contr. Release"},{"issue":"3","key":"10.1016\/j.canlet.2018.06.001_bib21","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1096\/fj.13-235440","article-title":"Unexpected low-dose toxicity of the universal solvent DMSO","volume":"28","author":"Galvao","year":"2014","journal-title":"Faseb. J."},{"issue":"5_suppl","key":"10.1016\/j.canlet.2018.06.001_bib22","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1177\/10600280940280S503","article-title":"Pharmacology and toxicology of cremophor EL diluent","volume":"28","author":"Dorr","year":"1994","journal-title":"Ann. Pharmacother."},{"issue":"41","key":"10.1016\/j.canlet.2018.06.001_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.tet.2007.07.085","article-title":"Rapid access to 3 -(N-Substituted ) -aminoquinolin -2 (1H)-ones using palladium-catalyzed C-N bond coupling reaction","volume":"63","author":"Messaoudi","year":"2007","journal-title":"Tetrahedron"},{"issue":"12","key":"10.1016\/j.canlet.2018.06.001_bib24","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.1021\/jo200680j","article-title":"A general copper powder-catalyzed Ullmann-type reaction of 3-Halo-4(1H)-quinolones with various nitrogen-containing nucleophiles","volume":"76","author":"Audisio","year":"2011","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.canlet.2018.06.001_bib25","series-title":"Mammalian Cell Viability","first-page":"33","article-title":"The XCELLigence system for real-time and label-free monitoring of cell viability","author":"Ke","year":"2011"},{"issue":"6","key":"10.1016\/j.canlet.2018.06.001_bib26","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.ejca.2003.11.021","article-title":"Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages","volume":"40","author":"Bibby","year":"2004","journal-title":"Eur. J. Canc."},{"issue":"1","key":"10.1016\/j.canlet.2018.06.001_bib27","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0014-5793(90)81016-H","article-title":"Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes","volume":"268","author":"Klibanov","year":"1990","journal-title":"FEBS Lett."},{"issue":"2","key":"10.1016\/j.canlet.2018.06.001_bib28","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0169-409X(95)00030-B","article-title":"Liposome circulation time and tumor targeting: implications for cancer chemotherapy","volume":"16","author":"Gabizon","year":"1995","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.canlet.2018.06.001_bib29","first-page":"297","article-title":"Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential","volume":"1","author":"Immordino","year":"2006","journal-title":"Int. J. Nanomed."},{"issue":"2","key":"10.1016\/j.canlet.2018.06.001_bib30","first-page":"215","article-title":"Liposomal trichostatin a: therapeutic potential in hormone-dependent and -independent breast cancer xenograft models","volume":"6","author":"Urbinati","year":"2011","journal-title":"Horm. Mol. Biol. Clin. Invest."},{"issue":"10","key":"10.1016\/j.canlet.2018.06.001_bib31","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1158\/1535-7163.MCT-05-0130","article-title":"Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells","volume":"4","author":"Morse","year":"2005","journal-title":"Mol. Canc. Therapeut."},{"issue":"2","key":"10.1016\/j.canlet.2018.06.001_bib32","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.canlet.2011.07.031","article-title":"A novel C-Terminal HSP90 inhibitor KU135 induces apoptosis and cell cycle arrest in melanoma cells","volume":"312","author":"Samadi","year":"2011","journal-title":"Canc. Lett."},{"issue":"4","key":"10.1016\/j.canlet.2018.06.001_bib33","doi-asserted-by":"crossref","first-page":"419","DOI":"10.18632\/oncoscience.156","article-title":"FS-93, an Hsp90 inhibitor, induces G2\/M arrest and apoptosis via the degradation of client proteins in oncogene addicted and derived resistant cancer cells","volume":"2","author":"Zhang","year":"2015","journal-title":"Oncoscience"},{"issue":"8","key":"10.1016\/j.canlet.2018.06.001_bib34","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1271\/bbb.110225","article-title":"SNX-2112, a novel Hsp90 inhibitor, induces G2\/M cell cycle arrest and apoptosis in MCF-7 cells","volume":"75","author":"Wang","year":"2011","journal-title":"Biosci. Biotechnol. Biochem."},{"issue":"3","key":"10.1016\/j.canlet.2018.06.001_bib35","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s00432-005-0047-7","article-title":"Hsp90 inhibitors cause G2\/M arrest associated with the reduction of Cdc25C and Cdc2 in lung cancer cell lines","volume":"132","author":"Senju","year":"2006","journal-title":"J. Canc. Res. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.canlet.2018.06.001_bib36","doi-asserted-by":"crossref","first-page":"6099","DOI":"10.1002\/j.1460-2075.1994.tb06956.x","article-title":"A role for Hsp90 in cell cycle control: wee1 tyrosine kinase activity requires interaction with Hsp90","volume":"13","author":"Aligue","year":"1994","journal-title":"EMBO J."},{"issue":"12","key":"10.1016\/j.canlet.2018.06.001_bib37","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.neo.2017.09.003","article-title":"Novel C-Terminal heat shock protein 90 inhibitors (KU711 and Ku757) are effective in targeting head and neck squamous cell carcinoma cancer stem cells","volume":"19","author":"Subramanian","year":"2017","journal-title":"Neoplasia N. Y. N"},{"key":"10.1016\/j.canlet.2018.06.001_bib38","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1186\/1471-2407-11-468","article-title":"Development and characterization of a novel C-Terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells","volume":"11","author":"Eskew","year":"2011","journal-title":"BMC Canc."},{"key":"10.1016\/j.canlet.2018.06.001_bib39","series-title":"Evaluating Dual Hsp90 and Hsp70 Inhibition as a Cancer Therapy; Topics in Medicinal Chemistry","first-page":"1","author":"Buckton","year":"2015"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383518303975?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383518303975?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T17:42:18Z","timestamp":1569001338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383518303975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":39,"alternative-id":["S0304383518303975"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2018.06.001","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antitumor activity of nanoliposomes encapsulating the novobiocin analog 6BrCaQ in a triple-negative breast cancer model in mice","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2018.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}